Just 30 percent of people who begin experiencing inflammatory back pain — an early symptom of spondyloarthritis — develop the disease, a study reports. The research, “Clinical evolution of patients with new‐onset inflammatory back pain: a population‐based cohort study,” appeared in the journal Arthritis & Rheumatology. Inflammatory back…
Sandoz recently announced the addition of Erelzi (etanercept) to the public drug plan in the Canadian provinces of British Columbia and Prince Edward Island for the treatment of multiple inflammatory diseases including ankylosing spondylitis. Erelzi was approved by Health Canada in April 2017 and launched in August 2017. Erelzi is…
Novartis recently reported that long-term radiographic data from a clinical trial showed that treatment of ankylosing spondylitis (AS) with Cosentyx (secukinumab) resulted in no disease progression in a vast majority of the patients analyzed. The multi-center, Phase 3 MEASURE I study (NCT01358175) showed that almost 80 percent of AS…
Patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Amgen‘s Enbrel (etanercept), which blocks tumor necrosis factor (TNF), experience a very early reparative response to therapy, new research shows. The study, “Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the…
Get regular updates to your inbox.